A research team from the University of Sydney examined social media content related to Alzheimer’s disease and blood-based biomarker testing across major platforms. The study analyzed 188 posts from accounts with a combined reach exceeding 114 million followers on Facebook, Instagram, and TikTok. The findings were published in the Journal of the American Geriatrics Society.
Blood tests detecting biomarkers such as p-tau217 and p-tau181 identify biological changes in the brain associated with Alzheimer’s disease. These tests are faster and more accessible than alternative diagnostic methods like brain imaging or lumbar punctures. However, major neurological organizations, including the Alzheimer’s Association, maintain that such tests should never be used to screen healthy individuals without symptoms.
The research identified concerning patterns in social media promotion of these tests. More than one-third of analyzed posts promoted testing for asymptomatic individuals, and accounts with financial interests were more than three times as likely to market the tests this way. Approximately 10 percent of posts came from doctors claiming the tests could be useful for screening in healthy people, with most originating from the United States. Researchers noted that some accounts had clear financial motivations, though others provided balanced information about limitations and potential harms.
Experts emphasize that positive biomarker results do not guarantee the development of dementia, as individuals may test positive yet never experience clinical symptoms. The tests should not be used independently for diagnosis and require combined assessment with other medical evaluations. No clear treatment pathway exists for healthy individuals who test positive, and research on available treatments has focused on patients with mild cognitive impairment or dementia rather than asymptomatic populations.
Potential harms include unnecessary diagnoses, psychological burden on patients and families, financial costs, and insurance implications. In Australia, tests ordered through doctors cost up to $400 and are not covered by Medicare, while online providers charge $600 or $365. Medical authorities stress that the tests should only be ordered by physicians in specific clinical circumstances where there is a high probability the person already has early Alzheimer’s disease.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI